MHRA Issues Defect Notification for Incorrect Tablet Counts in Xaggitin XL Prolonged-release Tablets

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 Medicines Defect Notification for several batches of Macarthys Laboratories Ltd T/A Martindale Pharma's Xaggitin XL Prolonged-release Tablets. The issue involves incorrect tablet counts in bottles, with reports of both missing and extra tablets. While the quality of the tablets is not affected, and no recall is being issued, healthcare professionals and patients are advised to be aware of this manufacturing defect.

Context

The Medicines and Healthcare products Regulatory Agency is responsible for ensuring the safety and efficacy of medicines in the UK. The Class 4 Medicines Defect Notification indicates a lower risk to patients but still requires attention. Xaggitin XL Prolonged-release Tablets are used for managing certain medical conditions, making accurate dosing essential for treatment effectiveness.

Why it matters

The notification from the MHRA highlights a significant issue in the pharmaceutical supply chain that could affect patient adherence to medication regimens. Accurate tablet counts are crucial for ensuring that patients receive the correct dosage. This defect may lead to confusion and potential health risks if patients take incorrect amounts of medication.

Implications

Patients relying on Xaggitin XL may experience disruptions in their treatment due to uncertainty about their medication supply. Healthcare providers may need to adjust prescriptions or offer alternative medications if patients report issues. The incident could prompt further scrutiny of manufacturing practices at Macarthys Laboratories Ltd and impact their reputation in the market.

What to watch

Healthcare professionals will need to monitor patient feedback regarding tablet counts and provide guidance on what to do if discrepancies are found. Patients should be vigilant and report any missing or extra tablets to their healthcare providers. The MHRA may issue further updates if the situation evolves or if additional batches are affected.